Literature DB >> 2898133

Neuroleptics and alternative treatments. Management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions.

R E Wragg1, D V Jeste.   

Abstract

Behavioral problems, and even psychotic symptoms, are universally acknowledged as among the most distressing consequences of dementia. A majority of patients experience either or both at some time during the course of dementia. Agitation is so common that accurate prevalence rates are difficult to ascertain; the available data suggest approximately 70 to 80 per cent of patients manifest this behavior in some form. Psychotic symptoms in some form occur less frequently, but perhaps affect up to half of demented patients at some time. Neuroleptic medications are among the psychoactive drugs most frequently prescribed for the demented elderly, yet they carry the risk of considerable morbidity from side effects, both acute (extrapyramidal syndromes, cardiovascular toxicity, anticholinergic effects) and chronic (tardive dyskinesia). They are most widely used for behavioral and psychotic symptoms; however, their efficacy for these problems is far from unequivocally established. The multiple medical problems of the elderly add to the complexity of diagnosing and managing these symptoms. Systematic delineation of the etiology, course, and prognosis of behavioral and psychotic symptoms may clarify the indications for such treatment. Further research on effective adjuncts and alternatives to neuroleptic treatment in the demented elderly may facilitate patient management, maximizing efficacy and reducing potential adverse consequences.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898133

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  8 in total

Review 1.  Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Authors:  Sandra S Kindermann; Christian R Dolder; Anne Bailey; Ira R Katz; Dilip V Jeste
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  Psychotropic drug use in a group of Dutch nursing home patients with dementia: many users, long-term use, but low doses.

Authors:  R T Koopmans; J M van Rossum; H J van den Hoogen; Y A Hekster; M A Willekens-Bogaers; C van Weel
Journal:  Pharm World Sci       Date:  1996-01

3.  Affective behavioural disturbances in Alzheimer's disease and ischaemic vascular disease.

Authors:  R Hargrave; L C Geck; B Reed; D Mungas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-01       Impact factor: 10.154

Review 4.  Optimal management of behavioural disorders associated with dementia.

Authors:  C A Class; L Schneider; M R Farlow
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 4.271

5.  Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation.

Authors:  Rita Moretti; Paola Torre; Rodolfo M Antonello; Giuseppe Cazzato; Antonio Bava
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 6.  Management of agitation in nursing home patients.

Authors:  N Billig
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

Review 7.  ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia.

Authors:  Dilip V Jeste; Dan Blazer; Daniel Casey; Thomas Meeks; Carl Salzman; Lon Schneider; Pierre Tariot; Kristine Yaffe
Journal:  Neuropsychopharmacology       Date:  2007-07-18       Impact factor: 7.853

8.  CNS medications as predictors of precipitous cognitive decline in the cognitively disabled aged: a longitudinal population-based study.

Authors:  Juha Puustinen; Janne Nurminen; Tero Vahlberg; Alan Lyles; Raimo Isoaho; Ismo Räihä; Sirkka-Liisa Kivelä
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2012-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.